氟尿嘧啶注射剂联合紫杉醇注射液治疗晚期胃癌的临床研究

Clinical trial of fluorouracil injection combined with paclitaxel injection in the treatment of advanced gastric cancer

目的观察氟尿嘧啶注射剂联合紫杉醇注射液治疗晚期胃癌的临床疗效及安全性。方法将38例晚期胃癌患者随机分为对照组18例与试验组20例。对照组予以口服2500 mg·m-2·d^(-1)卡培他滨,bid,给药2周后停药1周+第1天静脉滴注75 g·m^(-2)紫杉醇。试验组予以静脉滴注氟尿嘧啶0.5 g·d^(-1),qd,给药2周后停药1周+第1天静脉滴注75 g·m^(-2)紫杉醇。2组患者一个周期均为21 d,共治疗3个周期。比较2组患者的临床疗效和药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为95.00%(19/20例)和66.67%(12/18例),差异有统计学意义(P<0.05)。2组患者发生的药物不良反应主要有头痛、胃肠道反应和皮疹,试验组和对照组的药物不良反应发生率分别为15.00%和22.22%,差异无统计学意义(P>0.05)。结论氟尿嘧啶注射剂联合紫杉醇注射液治疗晚期胃癌的临床疗效显著,且不增加药物不良反应的发生率。

Objective To investigate the clinical efficacy and safety of fluorouracil injection combined with paclitaxel injection in the treatment of advanced gastric cancer. Methods Thirty patients with advanced gastric cancer were randomly divided into control group（ n = 18 cases）and treatment group（ n = 20 cases）. Control group was treated with oral2500 mg· m-2·d^-1capecitabine bid for 2 weeks,then stop 1 week,and intravenous infusion of 75 g · m^（-2）paclitarel,the first day. Treatment group was given fluorouracil 0. 5 g·d^-1qd for 2 weeks,then stop 1week,and intravenous infusion of 75 g · m^（-2）paclitarel,the first day.Two groups were treated with 3 cycles with 21 d per cycle. The clinical efficacy,and the adverse drug reactions were compared between two groups. Results After treatment,the total effective rates of treatment and control groups were 95. 00%（ 19/20 cases） and 66. 67%（ 12/18cases） with significant difference（ P〈0. 05）. The adverse drug reactions were based on headache,gastrointestinal reaction and rash in two groups,and the incidences were 15. 00% and 22. 22% without significant difference（ P〈0. 05）. Conclusion Fluorouracil injection combined with paclitaxel injection has a definitive clinical efficacy for the treatment of advanced gastric cancer,without increasing the incidence of adverse drug reactions.